159 related articles for article (PubMed ID: 33841635)
1. Synergistic anti-tumor effect of anti-PD-L1 antibody cationic microbubbles for delivery of the miR-34a gene combined with ultrasound on cervical carcinoma.
Liu Y; Jiang J; Liu C; Zhao W; Ma Y; Zheng Z; Zhou Q; Zhao Y
Am J Transl Res; 2021; 13(3):988-1005. PubMed ID: 33841635
[TBL] [Abstract][Full Text] [Related]
2. Ultrasound-Mediated Co-Delivery of miR-34a and sPD-1 Complexed with Microbubbles for Synergistic Cancer Therapy.
Qin YE; Tang WF; Xu Y; Wan FR; Chen AH
Cancer Manag Res; 2020; 12():2459-2469. PubMed ID: 32308482
[TBL] [Abstract][Full Text] [Related]
3. Synergistic anti-tumor effect of paclitaxel and miR-34a combined with ultrasound microbubbles on cervical cancer in vivo and in vitro.
Yu J; Zhao Y; Liu C; Hu B; Zhao M; Ma Y; Jiang J
Clin Transl Oncol; 2020 Jan; 22(1):60-69. PubMed ID: 31093891
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound targeting of microbubble-bound anti PD-L1 mAb to enhance anti-tumor effect of cisplatin in cervical cancer xenografts treatment.
Ma Y; Han J; Jiang J; Zheng Z; Tan Y; Liu C; Zhao Y
Life Sci; 2020 Dec; 262():118565. PubMed ID: 33038371
[TBL] [Abstract][Full Text] [Related]
5. Delivery of sPD1 gene by anti-CD133 antibody conjugated microbubbles combined with ultrasound for the treatment of cervical cancer in mice.
Liu Y; Zheng Z; Han J; Lin C; Liu C; Ma Y; Zhao Y
Toxicol Appl Pharmacol; 2023 Sep; 474():116605. PubMed ID: 37355104
[TBL] [Abstract][Full Text] [Related]
6. Nanobubbles containing PD-L1 Ab and miR-424 mediated PD-L1 blockade, and its expression inhibition to enable and potentiate hepatocellular carcinoma immunotherapy in mice.
Liu Y; Xie Q; Ma Y; Lin C; Li J; Hu B; Liu C; Zhao Y
Int J Pharm; 2022 Dec; 629():122352. PubMed ID: 36374798
[TBL] [Abstract][Full Text] [Related]
7. KCNQ1OT1 sponges miR-34a to promote malignant progression of malignant melanoma via upregulation of the STAT3/PD-L1 axis.
Wang X; Ren Z; Xu Y; Gao X; Huang H; Zhu F
Environ Toxicol; 2023 Feb; 38(2):368-380. PubMed ID: 36399467
[TBL] [Abstract][Full Text] [Related]
8. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
[TBL] [Abstract][Full Text] [Related]
9. UTMD promoted local delivery of miR-34a-mimic for ovarian cancer therapy.
Li Y; Du M; Fang J; Zhou J; Chen Z
Drug Deliv; 2021 Dec; 28(1):1616-1625. PubMed ID: 34319204
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.
Wang X; Li J; Dong K; Lin F; Long M; Ouyang Y; Wei J; Chen X; Weng Y; He T; Zhang H
Cell Signal; 2015 Mar; 27(3):443-52. PubMed ID: 25499621
[TBL] [Abstract][Full Text] [Related]
11. Effects of Cationic Microbubble Carrying CD/TK Double Suicide Gene and αVβ3 Integrin Antibody in Human Hepatocellular Carcinoma HepG2 Cells.
Li J; Zhou P; Li L; Zhang Y; Shao Y; Tang L; Tian S
PLoS One; 2016; 11(7):e0158592. PubMed ID: 27391603
[TBL] [Abstract][Full Text] [Related]
12. Liujunzi decoction exerts potent antitumor activity in oesophageal squamous cell carcinoma by inhibiting miR-34a/STAT3/IL-6R feedback loop, and modifies antitumor immunity.
Han Y; Fan X; Fan L; Wu Y; Zhou Z; Wang G; Guo L; Gao W; Chen Y; Gao Q
Phytomedicine; 2023 Mar; 111():154672. PubMed ID: 36701994
[TBL] [Abstract][Full Text] [Related]
13. [Polysaccharide of Atractylodis Macrocephalae Rhizoma inhibits expression of immune checkpoint PD-L1 by targeting miR-34a in esophageal carcinoma cells].
Han YC; Chen YL; Fan XQ; Shang YW; Chen X; Wang G; Shi B; Gao QL
Zhongguo Zhong Yao Za Zhi; 2022 Mar; 47(6):1658-1665. PubMed ID: 35347965
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound-mediated gene delivery with cationic versus neutral microbubbles: effect of DNA and microbubble dose on in vivo transfection efficiency.
Panje CM; Wang DS; Pysz MA; Paulmurugan R; Ren Y; Tranquart F; Tian L; Willmann JK
Theranostics; 2012; 2(11):1078-91. PubMed ID: 23227124
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA Opa interacting protein 5-antisense RNA 1 binds to micorRNA-34a to upregulate oncogenic PD-L1 in non-small cell lung cancer.
Qiao X; Zhao F
Bioengineered; 2022 Apr; 13(4):9264-9273. PubMed ID: 35411833
[TBL] [Abstract][Full Text] [Related]
16. Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment.
Zheng J; Huang J; Zhang L; Wang M; Xu L; Dou X; Leng X; Fang M; Sun Y; Wang Z
Biomater Res; 2023 Feb; 27(1):9. PubMed ID: 36759928
[TBL] [Abstract][Full Text] [Related]
17. miR-34a attenuates glioma cells progression and chemoresistance via targeting PD-L1.
Wang Y; Wang L
Biotechnol Lett; 2017 Oct; 39(10):1485-1492. PubMed ID: 28721584
[TBL] [Abstract][Full Text] [Related]
18. PD-L1-targeted microbubbles loaded with docetaxel produce a synergistic effect for the treatment of lung cancer under ultrasound irradiation.
Li T; Hu Z; Wang C; Yang J; Zeng C; Fan R; Guo J
Biomater Sci; 2020 Mar; 8(5):1418-1430. PubMed ID: 31942578
[TBL] [Abstract][Full Text] [Related]
19. Tumor perfusion enhancement by ultrasound stimulated microbubbles potentiates PD-L1 blockade of MC38 colon cancer in mice.
Li N; Tang J; Yang J; Zhu B; Wang X; Luo Y; Yang H; Jang F; Zou J; Liu Z; Wang Z
Cancer Lett; 2021 Feb; 498():121-129. PubMed ID: 33129956
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
